mlln
Navigation
Daily
Weekly
Monthly
Sector
Rank
Portfolio
Tools
Watchlist
My Portfolio
Mlln
About
Methodology
Score Criteria
Privacy
Upgrade to Pro
JD
James D.
Guest
Assets›Asset Details
A

AZN DCA Backtest — Dollar Cost Averaging Results

AstraZeneca PLC · Healthcare
Neutral
DCA Score
53
Updated Oct 11, 2026

AZN DCA Results: Key Findings

Investing $100 per week into AstraZeneca PLC (AZN) using Enhanced DCA over the past 5 years resulted in a total investment of $32,131, growing to a current value of $37,633 — a return of 17%.

Standard dollar cost averaging over the same period returned 12%, making Enhanced DCA +6% more effective with a lower average entry price of $136 versus standard DCA's $143.

AZN DCA backtest results: standard vs enhanced
PeriodStandard DCAEnhanced DCAAlpha
1-Year-11%-6%+5%
3-Year4%8%+4%
5-Year12%17%+6%
Pro subscribers only

Alpha you missed while unsubscribed

Our Pro members bought these signals. Here's what the returns look like — and what was left on the table.

You weren't subscribed
Major Weekly Buy Signal
Signal issued Oct 5, 2026 when our algorithm told users to buy ↗ $600
-0.4%
return to date
Current value of $600 position
$597
You weren't subscribed
Major Monthly Buy Signal
Signal issued Aug 3, 2026 when our algorithm told users to buy ↗ $2,598
+0.7%
return to date
Current value of $2,598 position
$2,617
Live Signal & Allocation %
Weekly Buy
As of Oct 9, 2026 close
345%
Next signal on or after Oct 12, 2026
Monthly Buy
As of Oct 9, 2026 close
345%
Next signal on or after Nov 2, 2026
Signals like these fire across 1,958 assets
AstraZeneca PLC DCA Calculator
Weekly and Monthly DCA Calculator
Frequency
Amount
$100
/week
1 Year
+5.0% alpha
Standard
Invested
$0
Value
$0
Return
-11.3%
Enhanced
Invested
$0
Value
$0
Return
-6.4%
24 targeted purchases · avg entry $170
3 Years
+4.2% alpha
Standard
Invested
$0
Value
$0
Return
3.8%
Enhanced
Invested
$0
Value
$0
Return
8.0%
73 targeted purchases · avg entry $147
5 Years
+5.5% alpha
Standard
Invested
$0
Value
$0
Return
11.6%
Enhanced
Invested
$0
Value
$0
Return
17.1%
120 targeted purchases · avg entry $136
Alpha Advantage · 5Y Enhanced DCA
+5.5%
Enhanced DCA achieved higher returns on the capital it deployed — with a lower average entry price than standard DCA
Avg entry$136 vs $143
5Y return17.1% vs 11.6%
Ending value ahead+$8,505
Backtest analysis

Dollar cost averaging into AZN — backtest results

Investing $100/week into AZN (AstraZeneca PLC) using standard dollar cost averaging over the past 5 years would have resulted in a total investment of $26,100 across 261 purchases, growing to a current value of $29,128 — a return of 12%.

Using Enhanced DCA — which automatically buys more when multiple signals agree conditions are right, and holds back when they don't — See the full methodology. The same $100/week base deployed $32,131 across 120 targeted purchases, growing to $37,633. That's a return of 17% — +6% more than standard DCA, with a lower average entry price of $136 vs $143.

Over the same 5-year period, standard weekly DCA into the S&P 500 (SPY) returned approximately 53%, so AZN's 17% Enhanced DCA return was below the index over the same period.

1-year weekly DCA results
Standard: $5,200 → $4,611 · -11%
Enhanced: $7,676 → $7,187 · -6%
3-year weekly DCA results
Standard: $15,700 → $16,296 · 4%
Enhanced: $19,036 → $20,562 · 8%
5-year weekly DCA results
Standard: $26,100 → $29,128 · 12%
Enhanced: $32,131 → $37,633 · 17%

Buying the dips for AstraZeneca PLC

i
Weekly buy signals for AZN. Larger markers are larger purchases, up to 6 times the base amount.
Frequently asked questions
How Enhanced DCA works
Multiple signals, one smarter decision
The buy multiplier is built from several inputs on the signal date: momentum (RSI), distance from the long term average, how far price has fallen from its yearly high, trend direction, and market fear (VIX). Each one scales the buy, so a week with a steep drawdown and elevated fear can produce a much larger buy.
Only what was known at the time
Every historical signal is computed from the prices available on its own date and nothing later, so the backtest cannot benefit from hindsight. Buys fill at the next day's open.
Same budget, working harder
Standard DCA buys the same amount every period. Enhanced DCA buys more when the model sees a dip and skips periods when it does not, so capital is concentrated at lower prices. The result can be a lower or higher total spend than standard DCA, and both are shown above.
Risk Disclosure: Past backtest performance does not guarantee future results. Dollar cost averaging into AstraZeneca PLC (AZN) involves investment risk, including potential loss of principal. AZN is a Healthcare stock whose price can fall as well as rise. This analysis is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before investing.
Explore other assets
Similar DCA backtests
Prices as of 9 October 2026 close · Backtest rebuilt 11 October 2026